AbbVie Receives Orphan Drug Designation for Investigational IL23 Inhibitor Risankizumab from the U.S. Food and Drug Administration for the Treatment of Pediatric Patients with Crohn's Disease

Orphan Drug Designation program provides orphan status to medications intended for the safe and effective treatment diagnosis or prevention of rare diseases1 Risankizumab is an investigational treatment being evaluated in immunological disorders inc...